Adverum生物技術 ADVM 深 滬
等待開盤 10-14 09:30:00 美东时间
4.16
-0.650
-13.51%
華盛通- 最 高4.945
- 今 開4.86
- 成交量 28.58万股
- 最 低 4.16
- 昨 收 4.81
- 總市值 8729.43万
- 52周最高 8.53
- 市盈率 靜 --
- 換手率 1.36%
- 52周最低 1.78
- 委 比 -21.21%
- 總股本 2098.42万
- 歷史最高 624.80
- 量 比 1.02
- 振 幅 16.32%
- 歷史最低 1.78
- 每 手 1
- 風險率 1.68%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 升至450美元，瑞穗上调特斯拉目标价；富国银行上调CoreWeave至"超配"，目标价升至170美元
今日重点评级关注：Guggenheim：维持MBX Biosciences"买入"评级，目标价从44美元升至84美元；Oppenheimer：维持MBX Biosciences"跑赢大市"评级，目标价从38美元升至80美元
09-24 10:23
Adverum Biotechnologies Completes Screening for Phase 3 Trial
An announcement from Adverum Biotechnologies ( ($ADVM) ) is now available. On S...
09-22 20:28
Adverum Biotechnologies Announces Completion of Screening for Pivotal Phase 3 ARTEMIS Trial of Ixo-vec for Wet Age-Related Macular Degeneration
Adverum Biotechnologies announced progress in its ARTEMIS Phase 3 trial for Ixo-vec in treating wet AMD. Screening closure is ahead of schedule, with full enrollment expected in 4Q 2025 and topline data readout accelerated to 1Q 2027. Ixo-vec, delivered via a one-time intravitreal injection, aims to provide long-term efficacy and reduce the need for frequent anti-VEGF injections. The trial compares Ixo-vec to aflibercept in both treatment-naïve a...
09-22 12:00
Chardan Capital Maintains Buy on Adverum Biotechnologies, Maintains $33 Price Target
Chardan Capital analyst Daniil Gataulin maintains Adverum Biotechnologies (NASDAQ:ADVM) with a Buy and maintains $33 price target.
08-13 22:26
Adverum Biotechnologies Q2 EPS $(2.34) Misses $(2.21) Estimate
Adverum Biotechnologies (NASDAQ:ADVM) reported quarterly losses of $(2.34) per share which missed the analyst consensus estimate of $(2.21) by 5.69 percent. This is a 60.27 percent decrease over losses of $(1.46) per
08-12 19:09
美股大行评级 | 潜在涨幅61.27%！Loop Capital上调英伟达目标价至250美元，维持"买入"评级
今日重点评级关注：Benchmark：维持特斯拉(TSLA)"买入"评级，目标价从350美元升至475美元>>
06-27 08:37
Mizuho Maintains Outperform on Adverum Biotechnologies, Lowers Price Target to $12
Mizuho analyst Graig Suvannavejh maintains Adverum Biotechnologies (NASDAQ:ADVM) with a Outperform and lowers the price target from $16 to $12.
06-26 22:59
Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Adverum Biotechnologies granted inducement awards, including stock options for 9,740 shares and RSUs for 4,870 shares, to two new employees under its 2017 Inducement Plan. The stock options have an exercise price of $2.22 per share and vest over four years, while RSUs vest over three years. Adverum is a clinical-stage company focusing on gene therapies for ocular diseases.
06-05 20:01
美股大行评级 | 潜在涨幅2840.31%！Mersana Therapeutics获Truist Securities升目标价至10美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130419824951111681.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Truist Securities：维持Mersana Therapeutics(MRSN)"买入"评级，目标价从9美元升至10美元</p> <p>• Guggenheim：维持Cabaletta Bio(CABA)"买入
05-17 08:44
美股大行评级 | 潜在涨幅1281.22%！Cabaletta Bio获Guggenheim升目标价至25美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130057143861719040.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持Cabaletta Bio(CABA)"买入"评级，目标价从23美元升至25美元</p> <p>• 瑞穗：维持Tectonic Therapeutic(TECX)"跑赢大市"评级，目标价从51美元
05-16 08:43
